大葉大學圖書館 |

Translational research methods for diabetes, obesity and cardiometabolic drug development[electronic resource] :a focus on early phase clinical studies /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.19
書名/作者:	Translational research methods for diabetes, obesity and cardiometabolic drug development : a focus on early phase clinical studies // edited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch.
其他作者:	Krentz, Andrew J.
出版者:	London : : Springer London :, 2015.
面頁冊數:	xii, 312 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Drug development.
標題:	Diabetes - Treatment.
標題:	Obesity - Treatment.
標題:	Medicine & Public Health.
標題:	Medicine/Public Health, general.
標題:	Internal Medicine.
標題:	Diabetes.
標題:	Metabolic Diseases.
標題:	Pharmacology/Toxicology.
標題:	Pharmaceutical Sciences/Technology.
ISBN:	9781447149200 (electronic bk.)
ISBN:	9781447149194 (paper)
內容註:	1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9. Assessment of cardiovascular safety of new diabetes drugs.
摘要、提要註:	This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development. Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
電子資源:	http://dx.doi.org/10.1007/978-1-4471-4920-0

Translational research methods for diabetes, obesity and cardiometabolic drug development[electronic resource] :a focus on early phase clinical studies /
Translational research methods for diabetes, obesity and cardiometabolic drug developmenta focus on early phase clinical studies /[electronic resource] :edited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch. - London :Springer London :2015. - xii, 312 p. :ill., digital ;24 cm.

1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9. Assessment of cardiovascular safety of new diabetes drugs.

This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development. Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.

ISBN: 9781447149200 (electronic bk.)

Standard No.: 10.1007/978-1-4471-4920-0doiSubjects--Topical Terms:

339189
Drug development.

LC Class. No.: RM301.25

Dewey Class. No.: 615.19

Translational research methods for diabetes, obesity and cardiometabolic drug development[electronic resource] :a focus on early phase clinical studies /
LDR:02606nam a2200313 a 4500 001 425606
003 DE-He213
005 20150722094808.0
006 m d
007 cr nn 008maaau
008 151119s2015 enk s 0 eng d
020 $a 9781447149200 (electronic bk.)
020 $a 9781447149194 (paper)
024 7 $a 10.1007/978-1-4471-4920-0 $2 doi
035 $a 978-1-4471-4920-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a MB $2 bicssc
072 7 $a MED000000 $2 bisacsh
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .T772 2015
245 0 0 $a Translational research methods for diabetes, obesity and cardiometabolic drug development $h [electronic resource] : $b a focus on early phase clinical studies / $c edited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch.
260 $a London : $b Springer London : $b Imprint: Springer, $c 2015.
300 $a xii, 312 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9. Assessment of cardiovascular safety of new diabetes drugs.
520 $a This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development. Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
650 0 $a Drug development. $3 339189
650 0 $a Diabetes $x Treatment. $3 402041
650 0 $a Obesity $x Treatment. $3 448188
650 1 4 $a Medicine & Public Health. $3 463493
650 2 4 $a Medicine/Public Health, general. $3 463494
650 2 4 $a Internal Medicine. $3 341979
650 2 4 $a Diabetes. $3 208538
650 2 4 $a Metabolic Diseases. $3 465858
650 2 4 $a Pharmacology/Toxicology. $3 463455
650 2 4 $a Pharmaceutical Sciences/Technology. $3 464319
700 1 $a Krentz, Andrew J. $3 528863
700 1 $a Heinemann, Lutz. $3 604703
700 1 $a Hompesch, Marcus. $3 604704
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-1-4471-4920-0
950 $a Medicine (Springer-11650)